In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Impact of the united states fda approved sex-specific cut-off values for high-sensitivity cardiac troponin t to diagnose myocardial infarction

Session Poster Session 3

Speaker Maria Rubini Gimenez

Event : ESC Congress 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : M Rubini Gimenez (Basel,CH), P Badertscher (Basel,CH), R Twerenbold (Basel,CH), J Boeddinghaus (Basel,CH), T Nestelberger (Basel,CH), C Mueller (Basel,CH)

Authors:
M. Rubini Gimenez1 , P. Badertscher1 , R. Twerenbold1 , J. Boeddinghaus1 , T. Nestelberger1 , C. Mueller1 , 1University Hospital Basel, Department of Cardiology - Basel - Switzerland ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 553

Background: High-sensitivity cardiac troponin (hs-cTn) T has been recently approved by the FDA to diagnose acute myocardial infarction (AMI) also in the United States (US). One uniform cut-off valus (19ng/L) has been recommended. However alternative sex-specific cut-offs have been also suggested (women 14ng/L, men 22ng/L). The values of these sex-specific values are higher as compared to the ones used outside the US.

Purpose and methods: We aim to explore the diagnostic reclassifications when using the FDA-approved sex-specific versus the FDA-approved uniform cut-offs for hs-cTnT in a large diagnostic multicentre study enrolling patients presenting with suspected MI to the ED. Patients presenting with ST-Segment-Elevation MI were excluded. The final diagnosis was centrally adjudicated by 2 independent cardiologists based on all available clinical information including serial measurements of hs-cTnT twice: once using the uniform cutoff value of 19ng/L and once using sex-specific cutoff values (women, 14ng/L; men, 22ng/L). The clinical impact of using sex-specific cut-offs was quantified by assessing diagnostic reclassifications when using sex-specific values. Duration of follow-up was 365 days.

Results: Among 4048 patients (1316 women and 2732 men), MI was diagnosed in 634 patients (15.7%, 168 women (12.8%) and 466 men (17.1%)) using the uniform cut-off value. Among these, concentrations of hs-cTnT were already greater or equal than the one overall cut-off value at ED presentation in 551 patients (sensitivity, 86.9% [95% CI, 84.0–89.4%], specificity (86.7% [95% CI, 85.5–87.8%]) with near-identical performance in women (sensitivity, 87.5% [95% CI, 81.5%-91.7%], specificity 87.7% [95% CI, 85.7%-89.6%]); and men (sensitivity, 86.7% [95% CI, 83.3%-89.7%], specificity 86.1% [95% CI, 84.7%-87.5%]).

After readjudication using sex-specific cut-offs, diagnostic reclassification occurred in 11 patients: 0.3% (95% CI, 0.1–0.5%) of all patients and 1.7% (95% CI, 0.9–3.0%) of patients with MI. In 4 women the diagnosis was upgraded from unstable angina (UA) to MI, and in 7 men the diagnosis was downgraded from MI to UA, overall resulting in 631 patients with a final adjudicated diagnosis of MI (versus 634 using the one overall cut-off (Figure). None of the reclassified patients died during 365-days follow-up. Among the 7 downgraded men 3 underwent PCI and 1 bypass grafting during the index admission. Among the 4 upgraded women, 3 underwent PCI.

Conclusion: Using the FDA-approved hs-cTnT cut-off values, the uniform 99th-percentile provides very high and near-identical sensitivity and specificity in women and men already at ED presentation. Sex-specific cut-off concentrations reclassify only a small percentage of patients. Accordingly, the uniform 99th-percentile should remain the standard of care also in the US.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are